Germany Pharmacovigilance Market Outlook

the pharmacovigilance market outlook for germany in 2018 to 2032 firmly places it on a par with other european countries, and even the developed world in terms of drug safety regulations. the german regulatory system is highly structured and robust and is known for its scientific rigor. as with other countries, german regulators adhere to international conference on harmonization (ich) guidelines on drug safety monitoring and evaluation. in line with the broader trends in healthcare, the pharmacovigilance market in germany is expected to witness positive growth over the next decade. with increasing prevalence of chronic diseases, regulatory requirements are likely to be intensified to ensure the safety of drugs available in the german market. at the same time, the rise of technology-assisted systems such as electronic prescribing, electronic health records and automated reporting systems should lead to further efficiencies in drug safety oversight. in addition, private players are expected to play an increasingly important role in germany's pharmacovigilance market, as they are likely to venture into the market for compliance and specialist services. this includes undertaking pre- and post-marketing studies to confirm the safety of drugs. moreover, with the amendments to the german drug act, there is likely to be an increased number of post-marketing surveillance studies to monitor the safety of drugs. the german government has also formulated guidelines related to regulatory compliance for medicines, biologics and biosimilars. this should encourage greater participation of the german pharmaceutical industry in pharmacovigilance activities. finally, greater awareness among healthcare professionals, as well as among patients and consumers, is also likely to be a major factor in germany's pharmacovigilance market in the years to come. overall, the pharmacovigilance market outlook for germany in 2018 to 2032 is expected to remain positive, with an increasing focus on drug safety regulation. the increasing role of technology, combined with regulations and guidelines for drug safety oversight, should drive growth in the coming years.